Novavax Inc (NVAX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.41B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novavax Inc (NVAX) Financials: Revenue, Profit and Cash Flow
Novavax reported revenue of $1.12B for the fiscal year ended Dec 31, 2025, up 64.7% from the year before. That year, net income was $440.30M with a net margin of 39.2%, operating cash flow was -$244.63M and free cash flow was -$251.02M. The quarter ended Sep 30, 2026 had revenue of $68.30M and net income of -$31.38M.
Revenue and Margins
The operating margin was 40.3% in the fiscal year ended Dec 2025, the highest of the 5 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $15.35M, a compound annual rate of 61.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.12B | +64.7% | 93.5% | 40.3% | 39.2% |
| Dec 2024 | $682.16M | -30.7% | 70.3% | -36.5% | -27.5% |
| Dec 2023 | $983.71M | -50.4% | 65.1% | -57.6% | -55.4% |
| Dec 2022 | $1.98B | +72.9% | 54.5% | -32.5% | -33.2% |
| Dec 2021 | $1.15B | +141.0% | 100.0% | -147.1% | -152.1% |
| Dec 2020 | $475.60M | +2448.5% | 100.0% | -87.6% | -87.9% |
| Dec 2019 | $18.66M | N/A | 100.0% | -646.1% | -711.0% |
| Dec 2018 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2017 | $31.18M | +103.1% | 100.0% | -550.8% | -589.5% |
| Dec 2016 | $15.35M | N/A | 100.0% | -1752.8% | -1823.5% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.12B | $682.16M | $983.71M | $1.98B | $1.15B | $475.60M | $18.66M | $0 | $31.18M | $15.35M |
| Cost of revenue | $73.04M | $202.74M | $343.77M | $902.64M | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $1.05B | $479.42M | $639.94M | $1.08B | $1.15B | $475.60M | $18.66M | $0 | $31.18M | $15.35M |
| Research and development | $342.32M | $391.17M | $737.50M | $1.24B | $2.53B | $747.03M | $113.84M | $173.80M | $168.44M | $237.94M |
| Operating income | $452.80M | -$248.93M | -$566.51M | -$644.74M | -$1.69B | -$416.72M | -$120.58M | -$173.92M | -$171.71M | -$269.11M |
| Net income | $440.30M | -$187.50M | -$545.06M | -$657.94M | -$1.74B | -$418.26M | -$132.69M | -$184.75M | -$183.77M | -$279.97M |
| EBITDA | $521.04M | -$108.04M | -$487.39M | -$604.71M | -$1.68B | -$398.23M | -$114.92M | -$164.23M | -$160.40M | -$259.33M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68.30M | $56.70M | $139.51M | $147.14M | $70.44M | $239.24M | $666.65M | $88.31M | $84.51M | $415.48M | $93.86M | $291.34M |
| Gross profit | $44.81M | $42.45M | $108.82M | $125.03M | $48.95M | $223.91M | $652.54M | $51.64M | $23.89M | $369.24M | $34.65M | $136.37M |
| Operating income | -$31.28M | -$54.91M | -$15.43M | $14.23M | -$178.02M | $101.07M | $515.51M | -$131.08M | -$134.02M | $161.00M | -$144.83M | -$183.57M |
| Net income | -$31.38M | -$53.39M | -$9.49M | $17.53M | -$202.38M | $106.51M | $518.65M | -$81.03M | -$121.30M | $162.38M | -$147.55M | -$178.39M |
Balance Sheet
As of Dec 2025, total debt of $246.72M exceeded cash and equivalents by $6.09M. Shareholder equity was negative, at -$127.75M, as total liabilities of $1.30B exceeded total assets of $1.18B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.18B | $1.56B | $1.80B | $2.26B | $2.58B | $1.58B | $172.96M | $207.98M | $302.49M | $394.30M |
| Current assets | $978.28M | $1.13B | $1.14B | $1.70B | $2.16B | $1.25B | $97.25M | $119.28M | $203.31M | $287.83M |
| Cash and equivalents | $240.63M | $530.23M | $568.50M | $1.34B | $1.52B | $553.40M | $78.82M | $70.15M | $106.31M | $144.35M |
| Total liabilities | $1.30B | $2.18B | $2.51B | $2.89B | $2.93B | $955.27M | $358.97M | $375.91M | $404.23M | $399.85M |
| Short-term debt | $2.51M | $7.01M | $5.14M | $324.88M | $0 | $322.04M | $1.26M | $24.63M | $34.69M | $29.59M |
| Long-term debt | $244.21M | $169.68M | $168.02M | $166.47M | $323.46M | $322.04M | $320.61M | $319.19M | $317.76M | $316.34M |
| Shareholder equity | -$127.75M | -$623.84M | -$716.93M | -$634.08M | -$351.67M | $627.21M | -$186.02M | -$167.94M | -$101.73M | -$5.55M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $888.00M | $955.58M | $1.04B | $1.18B | $1.18B | $1.34B | $1.29B | $1.56B | $1.71B | $1.82B | $1.35B | $1.80B |
| Total liabilities | $1.10B | $1.15B | $1.19B | $1.30B | $1.34B | $1.30B | $1.37B | $2.18B | $2.24B | $2.25B | $2.22B | $2.51B |
| Cash and equivalents | $222.46M | $191.46M | $228.36M | $240.63M | $268.02M | $253.74M | $263.34M | $530.23M | $573.63M | $680.16M | $480.59M | $568.50M |
| Shareholder equity | -$216.85M | -$190.71M | -$144.76M | -$127.75M | -$156.67M | $37.63M | -$75.64M | -$623.84M | -$526.44M | -$431.71M | -$867.08M | -$716.93M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$244.63M | -$87.26M | -$713.97M | -$415.94M | $322.95M | -$42.54M | -$136.62M | -$184.82M | -$144.48M | -$258.77M |
| Capital expenditures | $6.39M | $14.64M | $58.81M | $92.98M | $57.49M | $54.62M | $1.86M | $1.37M | $4.19M | $18.20M |
| Free cash flow | -$251.02M | -$101.90M | -$772.77M | -$508.92M | $265.46M | -$97.16M | -$138.48M | -$186.20M | -$148.66M | -$276.97M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $39.09M | N/A | N/A | $0 | $0 |
| Share repurchases | $0 | $0 | $3.59M | $5.26M | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$78.27M | -$204.04M | -$58.81M | -$92.98M | $100.15M | -$377.78M | $38.49M | $28.60M | $35.97M | $28.02M |
| Financing cash flow | $27.74M | $260.58M | $4.47M | $324.99M | $461.71M | $984.76M | $98.38M | $102.81M | $64.54M | $279.85M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$94.24M | -$72.81M | -$32.42M | -$39.48M | $107.80M | -$127.46M | -$185.50M | -$173.16M | -$144.81M | $314.27M | -$83.56M | -$176.78M |
| Capital expenditures | $1.02M | $588.00K | $1.27M | $2.25M | $2.02M | $527.00K | $1.59M | $2.25M | $2.01M | $3.13M | $7.25M | $9.08M |
| Free cash flow | -$95.26M | -$73.39M | -$33.69M | -$41.72M | $105.79M | -$127.99M | -$187.10M | -$175.41M | -$146.83M | $311.14M | -$90.81M | -$185.86M |
Frequently Asked Questions About NVAX
What is Novavax's annual revenue?
Novavax reported revenue of $1.12B for the fiscal year ended Dec 31, 2025.
How fast is Novavax's revenue growing?
Revenue was up 64.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -17.2%.
Is Novavax profitable?
Yes. Novavax reported net income of $440.30M for the fiscal year ended Dec 31, 2025, with a net margin of 39.2%.
How much free cash flow does NVAX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$244.63M minus capital expenditures of $6.39M produced free cash flow of -$251.02M.
How much debt does Novavax have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $244.21M, short-term debt of $2.51M and cash and equivalents of $240.63M.
NVAX pages: Overview, Earnings, Forecast, Financials, Competitors